RANK / NF-κB Reporter - HEK293 Recombinant Cell Line | 78102

RANK / NF-κB Reporter - HEK293 Recombinant Cell Line | 78102 | Gentaur US, UK & Europe Disrtribition

Category: Immunotherapy/Cell Line

Application: Screen for inhibitors of RANKL/RANK signaling in a cellular context

Background: RANK/RANKL/OPG pathway plays a significant role in osteoclast maturation, which are the major cells in charge of bone resorption. If RANKL binds to the receptor RANK instead of binding to its decoy receptor Osteoprotegerin (OPG), it activates the NF-κB pathway to promote osteoclast survival and proliferation, resulting in the resorption of bone. Therefore, abnormal production of RANKL or OPG can cause osteoporosis and other bone-related disorders, making the RANKL/RANK signaling pathway a valuable target for drug development.

Description: Recombinant HEK-293 cells expressing firefly luciferase gene under the control of Nuclear factor-κB (NF-κB) with constitMedium 1Gutive expression of human RANK (Receptor activator of nuclear factor-κB; TNFRSF11A; ref. seq. NM_003839.2).

Product Type: Cell Line

Shippement Condition: -80°C